All In Biotech

Drug Trial Radar · NCT07477639

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

A Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX319 in Subjects With Primary or Secondary Progressive Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

39

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Aug 2028

Study completion Jan 2029

Sponsor

Lead sponsor
Tr1X, Inc.Industry
Sponsor type
Industry
First posted
Mar 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive forms of MS? * At what dose does TRX319 work the best to treat participants with primary and or secondary progressive MS? * Is pre-conditioning (with Bendamustine) needed to allow TRX319 to better treat participants with primary and/or secondary progressive MS? Participants will be asked to be on study for up 1 year and may receive up to 3 total administrations of TRX319. While on study, participants will have blood tests and other assessments (MRI scans and lumbar punctures) done to understand the safety of TRX319 and how it may benefit their multiple sclerosis.

Conditions

  • Primary Progressive Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis (SPMS)
  • Multiple Sclerosis
  • Multiple Sclerosis (MS) Primary Progressive
  • Multiple Sclerosis (MS) Secondary Progressive

Interventions

  • TRX319Biological

    TRX319 is an investigational research cell therapy that may treat and provide long term relief to individuals suffering from Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis.

  • BendamustineDrug

    Administration of bendamustine prior to TRX319 infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of TRX319 infusion in subjects with Primary Progressive or Secondary Progressive Multiple Sclerosis.Time frame: From baseline until 12 months post TRX319 Infusion

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • UC San Diego

    La Jolla, California · Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Washington University, St. Louis

    St Louis, Missouri · Recruiting

  • Mt. Sinai

    New York, New York · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • Providence Swedish

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.